论文部分内容阅读
目的观察普罗布考对急性脑梗死患者血清超氧化物歧化酶(SOD)及高敏C反应蛋白(hsCRP)的影响。方法 52例急性脑梗死患者按随机数字表法分为常规治疗组25例和普罗布考组27例,常规治疗组给予常规治疗(包括抗血小板、降颅压及基础疾病治疗等),普罗布考组在常规治疗基础上加用普罗布考0.5g,2次/d,连服30d;并于治疗前后进行2组神经功能评估(NIHSS评分)及hsCRP和SOD测定。结果 2组治疗后较治疗前均有变化,神经功能改善,同时hsCRP下降,SOD上升;且普罗布考组治疗后血清SOD水平明显高于常规治疗组〔(98.0±25.4)vs(89.0±19.6)U/ml,P<0.05〕;hsCRP水平明显低于常规治疗组〔(2.7±0.4)vs(3.9±0.8)mg/L,P<0.05〕。结论普罗布考可降低急性脑梗死患者血清hsCRP水平、提高血清SOD水平,可能具有抗炎、抗氧化作用。
Objective To observe the effect of probucol on serum superoxide dismutase (SOD) and high sensitivity C-reactive protein (hsCRP) in patients with acute cerebral infarction. Methods Fifty-two patients with acute cerebral infarction were randomly divided into routine treatment group (n = 25) and probucol group (n = 27). Conventional treatment group was given routine treatment (including antiplatelet, intracranial pressure and underlying disease treatment) The test group was given probucol 0.5 g twice daily for 30 days on the basis of routine treatment. The neurological function (NIHSS score), hsCRP and SOD were measured before and after treatment. Results The changes of neurological function, the decrease of hsCRP and the increase of SOD in the two groups after treatment were significantly higher than those in the routine treatment group [(98.0 ± 25.4 vs 89.0 ± 19.6 ) U / ml, P <0.05]. The hsCRP level was significantly lower than that of the conventional treatment group (2.7 ± 0.4 vs 3.9 ± 0.8 mg / L, P <0.05). Conclusion Probucol can reduce serum hsCRP levels in patients with acute cerebral infarction and increase serum SOD levels, which may have anti-inflammatory and anti-oxidative effects.